- Country: Germany
- Summary: Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dimethyl Fumarate, Atc D05bx01 for the Period January 1St, 2024 - December 31St, 2025
- DET Ref No: 92348515
- Deadline: 05 Dec 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: EUR 1.00
- Notice Type: Tender
- Document Ref. No.: 695925-2023
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the relevant legal regulations for the award of public contracts, seeet a regular process of active ingredient-related, formal award procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicinal products to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient dimethyl fumarate, ATC D05BX01, intends to use DAK-Ghealth to conclude drug discount agreements with as many interested pharmaceutical companies as possible until new drug discount agreements come into force. For the above-mentioned active ingredient, the ARGE intends to use dimethyl fumarate with as many as possible, at least all interested pharmaceutical companiesCompanies to conclude drug framework discount agreements. The following health insurance companies belong to the ARGE Dimethyl Fumarate: - DAK-Gesundheit - Techniker Krankenkasse - Kaufmannische Krankenkasse - HEK - Hanseatic Health Insurance Fund - Hkk - Handelskrankenkasse - BARMER together hereinafter "Krankenkassen". A discount agreement in the sense of the approval model for the above-mentioned active ingredient comes into force for the first time on January 1st, 2024 and ends on December 31st, 2025. Regardless of this, it ends automatically when the exclusive agreement comes into force.
Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINConclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dimethyl Fumarate, Atc D05bx01 for the Period January 1St, 2024 - December 31St, 2025 - Germany Tender
The DAK HEALTH, a Government sector organization in Germany, has announced a new tender for Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Dimethyl Fumarate, Atc D05bx01 for the Period January 1St, 2024 - December 31St, 2025. This tender is published on GermanyTenders under DET Ref No: 92348515 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-12-05.
The estimated tender value is EUR 1.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
